Cardiovascular Drugs and Therapy 1989; 3: 99-103
© Kluwer Academic Publishers. Printed in the U.S.A.

AUTHOR INDEX CARDIOVASCULAR DRUGS AND THERAPY VOLUME 2

Agmon J, *see* Strasberg, 801
Akatsuka N, *see* Isshiki, 325
Ambrosio G, Chiariello M. Can free radicals explain reperfusion damage? 609
Amende I, Hermann G, Simon R, Wenzlaff P, Lichtlen PR Intracoronary nisoldipine: Effects on acute myocardial ischemia during coronary angioplasty, 807
Amery A, *see* Birkenhager, 275
Araujo LI, Camici P, Spinks TJ, Jones T, Maseri A. Abnormalities in myocardial metabolism in patients with unstable angina as assessed by positron emission tomography. 41
Arndt JW, *see* De Nooijer, 673

Baba K, *see* Mulrow, 463
Ballantyne D, *see* Northcote, 549
Baroni S, *see* Cardillo, 533
Bassenge E, Stewart DJ. Interdependence of pharmacologically-induced and endothelium-mediated coronary vasodilation in antianginal therapy, 27
Beaufils P, Kolsky H, Haiat R, Castaigne A., Slama R. The influence of molsidomine on infarct size: An acute post-infarction pilot study with 303 patients, 127
Bette L, *see* Rettig, 401
Birkenhager WH, De Leeuw PW, Amery A, Staessen J. Treatment of hypertension in the elderly 275
Bleifeld W, *see* Hamm, 333
Blokland JAK, *see* De Nooijer, 673
Boccia AS, *see* Greco, 791
Bode C, *see* Kubler, 121
Bolognesi R, *see* Pezzarossa, 669
Bracchetti D, *see* Cantelli, 83
Bruschke AVG, *see* De Nooijer, 673
Bulpitt CJ, Fletcher AE. Measurement of the quality of life in congestive heart failure - influence of drug therapy, 419

Camici P, *see* Araujo, 41
Camm AJ, *see* Linker, 165
Cantelli I, Bracchetti D. Combination of positive intropic and vasodilating substances in congestive heart failure, 83
Caralis DG, Kyriakides Z. Preload or afterload reduction: Which is more beneficial for patients with ischemic heart disease? 79
Cardillo C, Musumeci V, Mores N., Baroni S, Cremona G., Tutinelli F, Folli G. Twenty-four hour blood pressure monitoring after a single dose of sustained-release verapamil, 533
Castaigne A, *see* Beaufils, 127
Cats VM, *see* De Nooijer, 673
Chassing A, *see* Flammang, 771
Chiariello M, *see* Ambrosio, 609
Chimiuenti M, Regazzi MB, La Rovere MT, Salerno JA, Previtali M, Montericcio V, Rondanelli R, Montemartini C. Comparison of the effectiveness of dihydroquinidine and quinidine on ventricular ectopy after acute and chronic administration, 679
Cimicchi MC, *see* Pezzarossa, 669
Coetzee WA, *see* Opie, 623
Cohn JN, *see* Kubo, 653
Cohn PF. Indications for treatment of silent myocardial ischemia, 67
Cooke JP, Shepherd JT, Vanhoutte PM. Vasoconstriction induced by ouabain in the canine coronary artery: Contribution of adrenergic and nonadrenergic responses, 255
Cooke MBD, *see* Northcote, 549
Cosson G, *see* Flammang, 771
Cozzi E, *see* Ghiringhelli, 211
Cremona G, *see* Cardillo, 533
Crome R, Manning AS. Allopurinol and reperfusion-induced arrhythmias: Increased protection by simultaneous administration of anti-oxidant enzymes, 295
Cupples A, *see* Kannel, 387

D'Alterio D, *see* Greco, 791
Davies W, Jazayeri M, Tchou P. Marked Q-T prolongation due to encainide therapy, 283
Davy J-M, *see* Keren, 637
De Bari M, *see* Marchionni, 529
De Feyter PJ, Serruys PW, Hugenholtz PG. Indications for coronary angioplasty in acute myocardial ischemic syndromes, 93
De Leeuw PW, *see* Birkenhager, 275
De Nooijer RC, Van der Wall EE, Cats VM, Van Herpen G, Van der Laarse A, Blokland JAK, Jaarsma W, Arndt JW, Bruschke AVG. The acute effects of intravenous nisoldipine on left ventricular function 24 to 72 hours after uncomplicated acute myocardial infarction, 673
Dei Cas L, Metra M, Nodari S, Riva S, Manca C, Visioli O. Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure, 221
Dene H, *see* Rapp, 487
Depelchin P, Sobolski J, Jottrand M, Flament C. Secondary prevention after myocardial infarction: Effects of beta-blocking agents and calcium antagonists, 139
Descheper CF, *see* Gardner, 479
Doi Y, *see* Mulrow, 463
Dorian P, *see* Keren, 637
Drake-Holland AJ, Noble MIM, Pugh S, Mills C. Effect of intravenous ketanserin on the human action potential duration at fixed heart rate, 239
Drexler H, *see* Meinertz, 413
Durakovic A, *see* Durakovic, 757
Durakovic Z, Ivanovic D, Durakovic A. Digoxin-like substance in the serum of uremic patients before and after hemodialysis, 757
Dzau VJ, Pratt RE, Paul M, Nakamura N. Molecular studies of human renin synthesis and gene expression. 459

Ebner V, *see* Wimmer, 661
Elson JJ, *see* Fogoros, 171
Euler DE, Hughes PJ, Scanlon PJ. Comparison of the effects of acute and chronic beta-blockade on infarct size in the dog after circumflex occlusion, 231
Euler DE, Scanlon PJ. The duration of coronary occlusion influences adrenergic contributions to reperfusion ventricular arrhythmias, 513

Feldman RL, Prida XE, Lambert CR, Hill JA. Systemic and coronary hemodynamics of labetalol in normotensive patients with ischemic heart disease, 355
Ferrara AL, *see* Pasanisi, 219
Ferrucci L, *see* Marchionni, 529
Fiedler SB, *see* Fogoros, 171
Flament C, *see* Depelchin, 139
Flammang D, Waynberger M, Paillet R, Pruvot C, Cosson G, Chassing A. Myocardial infarction: Is bepridil, a new calcium antagonist, able to improve the course of the acute phase? 771
Fletcher AE, *see* Bulpitt, 419
Fogoros RN, Fiedler SB, Elson JJ. Efficacy of phenytoin in suppressing inducible ventricular tachyarrhythmias, 171
Folli G, *see* Cardillo, 533
Fox K, Quyyumi AA. Labetalol in normotensive patients with angina pectoris, 363
Franco-Saenz R, *see* Mulrow, 463
Friedman HS, *see* Mokraoui, 569
Frishman WH. Properties of labetalol, a combined alpha and beta-blocking agent, relevant to the treatment of myocardial ischemia, 343
Frohlich ED, *see* Isshiki, 539

Gardner DG, Wu J, La Pointe MC, Hedges BK, Deschepper CF. Expression of the gene for the atrial natriuretic peptide in cardiac myocytes in vitro, 479
Geller M, *see* Kirch, 205
Gersh BJ, *see* Lavie, 601
Ghiringhelli S, Cozzi E, Tsialtas D. Hemodynamic effects of celiprolol at rest and during exercise: A comparison with enalapril, 211
Gnudi A, *see* Pezzarossa, 669
Goerig M, Habenicht A, Schettler G. Atherosclerosis and fish oil, 281
Greco R, D'Alterio D, Schiattarella M, Musto B, Wolff S., Boccia AS, Mininni N. Intravenous amiodarone in acute anterior myocardial infarction: A controlled study, 791
Guyatt G, *see* Jaeschke, 727

Habenicht A, *see* Goerig, 281
Haber RH, LeJemtel T, Sonnenblick EH. The pathophysiologic profile of congestive heart failure, 397
Haiat R, *see* Beaufils, 127
Hamanaka Y, *see* Kuzuya, 693
Hamm CW, Bleifeld W. Unstable angina: Current concepts of medical management, 333
Harrison DC. Arrhythmia prophylaxis after acute myocardial infarction, 788
Hayakawa H, *see* Kishida, 831
Hearse DJ. Ischemia at the crossroads? 9
Hedges BK, *see* Gardner, 479
Herrman G, *see* Amende, 807
Hertrich FF, Winkelmann BR, Leinberger H. Isometric exercise for the evaluation of vasodilatory therapy in severe congestive heart failure, 287
Higashimori K, *see* Inagami, 453
Hill JA, *see* Feldman, 355
Hoshida S, *see* Kuzuya, 693
Hosono M, Satoh K, Taira N. T-1583 and forskolin are similar in their cardiac effects and dissimilar in their vascular effects, 245
Hsueh WA. Renin in the female reproductive system, 473
Hugenholtz PG, *see* De Feyter, 93
Hughes PJ, *see* Euler, 231
Hunt SA. Drug management of the cardiac transplant patient, 687

Inagaki Y, *see* Kishida, 831
Inagami T, Mizuno K, Nakamura M, Pandey KN, Naruse M, Naruse K, Misono K, Okamura T, Kawamura M, Higashimori K. The renin-angiotensin system: An overview of its intracellular function, 453
Isshiki T, Akatsuka N, Saito T, Tsuneyoshi H, Ohno M, Nakamura M, Namiki T, Oka H. Comparison of functional responses of canine coronary artery and saphenous vein, 325
Isshiki T, Pegram BL, Frohlich ED. Immediate and prolonged hemodynamic effects of TA-3090 on spontaneously hypertensive (SHR) and normal Wistar-Kyoto (WKY) rats, 539
Ivanovic D, *see* Durakovic, 757

Jaarsma W, *see* De Nooijer, 673
Jaeschke R, Guyatt G. Why different trials on digitalis give conflicting data, 727
Jazayeri M, *see* Davies, 283
Jones T, *see* Araujo, 41
Jottrand M, *see* Depelchin, 139
Just H, *see* Meinertz, 413

Kahn S, *see* Rein, 561
Kamada T, *see* Kuzuya, 693
Kannel WB, Cupples A. Epidemiology and risk profile of cardiac failure, 387
Kaplan NM. Calcium and blood pressure, 269
Kardash MM, *see* Kohli, 523
Katz A, *see* Strasberg, 801
Katz AM. Are inotropic agents contraindicated in congestive heart failure? 747
Kawai C, *see* Susawa, 305
Kawai C, *see* Kumada, 751
Kawamura M, *see* Inagami, 453
Keren A, Dorian P, Davy J-M, Opie LH. Effects of magnesium on ischemic and reperfusion arrhythmias in the rat heart and electrophysiologic effects of hypermagnesemia in the anesthetized dog, 637
Khurmi NS, *see* Kohli, 523
Kihara Y, *see* Susawa, 305
Kimura Y, *see* Kuzuya, 693
Kingma JG, Yellon DM. Limitation of myocardial necrosis with verapamil during sustained coronary occlusion in the closed-chest dog, 313
Kirch W, Santos SR, Geller M, Monig H, Stenzel J. Ohnhaus EE. Influence of nitrendipine and verapamil on plasma levels, urinary excretion, and beta-blocking effect of metropolol, 205

Kishida H. Inagaki Y, Hayakawa H, Kurita A, Saito T, Kitagawa H. The effect of nitroglycerin ointment on exercise-induced angina: A multicenter trial, 831
Kitabatake A, *see* Kuzuya, 693
Kitagawa H, *see* Kishida, 831
Kjekshus JK. According to MIAMI and ISIS-1 trials, can a general recommendation be given for beta-blockers in acute myocardial infarction? 113
Klein HH, Pich S. Nebendahl K, Kreuzer H. Comparative study on the enhancement of ischemic tolerance by intracoronary pretreatment with three calcium antagonists in pig hearts, 815
Kodama K, *see* Kuzuya, 693
Kohli RS, Khurmi NS, Kardash MM, Lahiri A, Raftery EB. Oral nitroglycerin in agina pectoris - evaluation of effect by computerized exercise testing using two different doses, 523
Kolsky H, *see* Beaufils, 127
Kreuzer H, *see* Vogt, 647
Kreuzer H, *see* Klein, 815
Kubler W, Bode C, Schomig A, Schuler G, Schwartz F. What is established in thrombolytic therapy of acute myocardial infarction? Pharmacological approaches, 121
Kubo SH, Rector TS, Strobeck HE, Cohn JN. OPC-8212 in the treatment of congestive heart failure: Results of a pilot study, 653
Kumada T, Kawai C. Can new inodilators displace digitalis in the therapy of congestive heart failure? 751
Kurita A, *see* Kishida, 831
Kusano E, *see* Mulrow, 463
Kuzuya T, Kimura Y, Hoshida S, Kodama K, Nakamura N, Hamanaka Y, Kitabatake A, Kamada T, Tada M. The effect of CV-4151, a selective inhibitor of thromboxane synthetase, on prostanoid formation and platelet aggregation in humans, 693
Kyriakides Z, *see* Caralis, 79

La Pointe MC, *see* Gardner, 479
La Rovere MT, *see* Chimiuenti, 679
Lahiri A, *see* Kohli, 523
Lambert C, Rouleau JL. How to digitalize and to maintain optimal digoxin levels in congestive heart failure, 717
Lambert CR, *see* Feldman, 355
Lamm G. Risk factor intervention and prognosis after acute myocardial infarction, 133
Lavanchy N, Martin J, Rossi MA. Comparative study of the effects of acebutolol, atenolol, d-propranolol and dl-propranolol on the alterations in energy metabolism caused by ischemia and reperfusion: A 31P NMR on the isolated rat heart, 501
Lavie CJ, Murphy JG, Gersh BJ. The role of beta-receptor and calcium entry blocking agents in acute myocardial infarction in the thrombolytic era: Can the results of thrombolytic reperfusion be enhanced? 601
LeJemtel T, *see* Haber, 397
Leinberger H, *see* Hertrich, 287
Levang OW, *see* Rein, 561
Lewis HD, Jr. Which role for antiplatelet and anticoagulant drugs in unstable angina pectoris, 103
Lichtlen PR. The combination of antianginal drugs: Effects and indications, 47
Lichtlen PR, *see* Amende, 807
Linker NJ, Camm AJ. Drug effects on the sinus node. A clinical perspective, 165
Lucchesi B, *see* Werns, 761

Manca C, *see* Dei Cas, 221, 669
Manning AS, *see* Crome, 295
Marchionni N, De Bari M, Ferrucci L, Moschi G, Schneeweiss A. Comparative study of time-course of hemodynamic effect of isosorbide dinitrate spray and sublingual tablets in patients with pulmonary congestion, 529
Marotta T, *see* Pasanisi, 219
Martin J, *see* Lavanchy, 501
Maseri A, *see* Araujo, 41
Maupoil V, Rochette L. Evaluation of free radical and lipid peroxide formation during global ischemia and reperfusion in isolated perfused rat heart, 615
Meinertz T, Drexler H, Just H. Therapeutic advances in heart failure, 413
Melniker LA, *see* Mokraoui, 569
Metra M, *see* Dei Cas, 221
Mills C, *see* Drake-Holland, 239
Mininni N, *see* Greco, 791
Misono K, *see* Inagami, 453
Miyazaki S, *see* Susawa, 305
Mizuno K, *see* Inagami, 453
Mokraoui AM, Friedman HS, Melniker LA, Nguyen TN. Effects of acetyl strophanthidin on duration of atrial fibrillation in the neurally-intact and blockaded dog, 569
Monig H, *see* Kirch, 205
Montemartini C, *see* Chimiuenti, 679
Montericcio V, *see* Chiminuenti, 679
Mores N, *see* Cardillo, 533
Moschi G, *see* Marchionni, 529
Mulrow PJ, Kusano E, Baba K, Shier D, Doi Y, Franco-Saenz R, Stoner G, Rapp J. Adrenal renin: A possible local hormonal regulator of aldosterone production, 463
Murphy JG, *see* Lavie, 601
Musto B, *see* Greco, 791
Musumeci V, *see* Cardillo, 533
Myhre HO, *see* Rein, 561

Nakamura M, *see* Isshiki, 325
Nakamura M, *see* Inagami, 453
Nakamura N, *see* Dzau, 459
Nakamura N, *see* Kuzuya, 693
Nakamura Y, *see* Susawa, 305
Namiki T, *see* Isshiki, 325
Naruse K, *see* Inagami, 453
Naruse M, *see* Inagami, 453
Nebendahl K, *see* Klein, 815
Neuhaus KL, *see* Vogt, 647
Nguyen TN, *see* Mokraoui, 569
Noble MIM, *see* Drake-Holland, 239
Nodari S, *see* Dei Cas, 221
Noll OBG. Additional molsidomine in refractory unstable angina pectoris, 107
Northcote RJ, Cooke MBD, Ballantyne D. Left ventricular function and beta-blockers: Does intrinsic sympathomimetic activity have any influence during chronic therapy? 549

Ohnhaus EE, *see* Kirch, 205
Ohno M, *see* Isshiki, 325

Oka H, *see* Isshiki, 325
Okamura T, *see* Inagami, 453
Opie LH. Calcium channel antagonists. Part IV. Side-effects and contraindications, drug interactions and combinations, 177
Opie LH. Calcium channel antagonists. Part V. Second-generation agents, 191
Opie LH. Role of vasodilation in the antihypertensive and antianginal effects of labetalol: Implications for therapy of combined hypertension and angina, 369
Opie LH, Coetzee WA. Role of calcium ions in reperfusion arrhythmias: Relevance to pharmacologic intervention, 623
Opie LH, *see* Keren, 637
Orlandi N, *see* Pezzarossa, 669
Ovsyccher IA, *see* Strasberg, 801

Packer M. Does digitalis work in chronic heart failure? The end of a 200-year-old controversy. 743
Paillet R, *see* Flammang, 771
Pandey KN, *see* Inagami, 453
Parker JO. Nitrate tolerance in angina pectoris, 823
Parratt JR. Pathophysiology of myocardial ischemia: Importance of platelet vessel wall interactions, 35
Pasanisi F, Ferrara AL, Marotta T. A combination of verapamil, captopril, and diuretic in the treatment of severe hypertension, 219
Paul M, *see* Dzau, 459
Pegram BL, *see* Isshiki, 539
Perrone A, *see* Pezzarossa, 669
Pezzarossa A, Cimicchi MC, Orlandi N, Gnudi A, Manca C, Perrone A, Bolognesi R. Lack of effect of nicardipine and diltiazem on glucose- and arginine-induced insulin release in obese subjects, 669
Pich S, *see* Klein, 815
Poole-Wilson PA, Robinson K. Digoxin - a redundant drug in congestive heart failure, 733
Pratt RE, *see* Dzau, 459
Previtali M, *see* Chimiuenti, 679
Prida XE, *see* Feldman, 355
Pruvot C, *see* Flammang, 771
Pugh S, *see* Drake-Holland, 239

Quyyumi AA, *see* Fox, 363

Raftery EB, *see* Kohli, 523
Rapp J, *see* Mulrow, 463
Rapp JP, Dene H. Recruitment of the left ventricle for production of atrial natriuretic factor in Dahl salt-hypertension rats, 487
Rechavia E, *see* Strasberg, 801
Rector TS, *see* Kubo, 653
Regazzi MB, *see* Chimiuenti, 679
Rein KA, Stenseth R, Myhre HO, Levang OW, Kahn S. Time-related changes in the Starling forces following extracorporeal circulation, 561
Rettig GF, Bette L. Current therapy of acute heart failure, 401
Righetti A, *see* Rutishauser, 61
Riva S, *see* Dei Cas, 221
Robinson K, *see* Poole-Wilson, 733
Rochette L, *see* Maupoil, 615
Rondanelli R, *see* Chimiuenti, 679
Rossi MA, *see* Lavanchy, 501
Rouleau JL, *see* Lambert, 717
Roy P, *see* Rutishauser, 61
Rutishauser W, Righetti A, Roy P. Silent ischemia: A relevant problem in patients with coronary artery disease? 61

Sagie A, *see* Strasberg, 801
Saito T, *see* Isshiki, 325
Saito T, *see* Kishida, 831
Salerno JA, *see* Chimiuenti, 679
Santos SR, *see* Kirch, 205
Sasayama S, *see* Susawa, 305
Satoh K, *see* Hosono, 245
Scanlon PJ, *see* Euler, 231, 513
Schaper J, Schaper W. Time course of myocardial necrosis, 17
Schaper W, *see* Schaper, 17
Schettler G, *see* Goerig, 281
Schettler G. The role of diet and drugs in lowering serum cholesterol in the postmyocardial infarction patient, 795
Schiattarella M, *see* Greco, 791
Schiffrin EL. Regulation of receptors for atrial natriuretic peptide in the rat and human, 493
Schlemmer M, *see* Wimmer, 661
Schneeweiss A, *see* Marchionni, 529
Schomig A, *see* Kubler, 121
Schuler G, *see* Kubler, 121
Schulz W. Nonresponsiveness to antianginal therapy - A frequent problem? 71
Schwarz F, *see* Kubler, 121
Sclarovsky S, *see* Strasberg, 801
Serruys PW, *see* De Feyter, 93
Shepherd JT, *see* Cooke, 255
Shier D, *see* Mulrow, 463
Simon R, *see* Amende, 807
Slama R, *see* Beaufils, 127
Sobolski J, *see* Depelchin, 139
Sonnenblick EH, *see* Haber, 397
Spinks TJ, *see* Araujo, 41
Staessen J. *see* Birkenhager, 275
Stenseth, *see* Rein, 561
Stenzel J. *see* Kirch, 205
Stewart DJ, *see* Bassenge, 27
Stoner G, *see* Mulrow, 463
Strasberg B, Sagie A, Rechavia E, Katz A, Ovsysccher IA, Sclarovsky S, Agmon J. Deleterious effects of intravenous verapamil in Wolff-Parkinson-White patients and atrial fibrillation, 801
Strobeck JE, *see* Kubo, 653
Susawa T, Kihara Y, Miyazaki S, Nakamura Y, Sasayama S, Kawai C. Acute hemodynamic effects of MDL 19205 on conscious dogs with mitral regurgitation, 305

Tada M, *see* Kuzuya, 693
Taira N, *see* Hosono, 245
Taylor SH. Drug therapy of chronic heart failure, 407
Tchou P, *see* Davies, 283
Tsialtas D, *see* Ghiringhelli, 211
Tsuneyoshi H, *see* Isshiki, 325
Tutinelli F, *see* Cardillo, 533

Van Herpen G, *see* De Nooijer, 673
Van der Laarse A, *see* De Nooijer, 673
Van der Wall EE, *see* De Nooijer, 673
Vanhoutte PM, *see* Cooke, 255

Visioli O, *see* Dei Cas, 221
Vogt A, Neuhaus KL, Kreuser H. Pathophysiologic arguments for vasodilators in cardiac failure, 647

Waynberger M, *see* Flammang, 771
Wenzlaff P, *see* Amende, 807
Werns SW, Luccchesi B. Myocardial ischemia and and reperfusion: The role of oxygen radicals in tissue injury, 761
Wimmer M, Schlemmer M, Ebner F. Hemodynamic effects of nifedipine and oxygen in children with pulmonary hypertension, 661
Winkelman BR, *see* Hertrich, 287
Wolff S, *see* Greco, 791
Wu J, *see* Gardner, 479

Yellon DM, *see* Kingma, 313

Cardiovascular Drugs and Therapy 3: 1989: 105-108
© Kluwer Academic Publishers. Printed in the U.S.A.

SUBJECT INDEX CARDIOVASCULAR DRUGS AND THERAPY VOLUME 2

ACE inhibitors, 413, 419
Acebutolol and myocardial ischemia in rat heart, 501
Acetyl strophanthidin and atrial fibrillation in dog, 569
Action potential duration, 239
Acute myocardial infarction 93, 121
  See also myocardial infarction 127, 601, 673
  Amiodarone and, 791
  Arrhythmia prophylaxis, 788
  Beta-blockade for, 113
  Cholesterol, 133
  Coronary artery disease, 133
  Hypertension, 133
  Risk factors, 133
  Smoking, 133
  Treatment of, 788
  Thrombolytic therapy of, 121
Adenylate cyclase activator, 245
Adrenergic antagonism, 343
Adrenergic blockade, 343
Adrenergic responses and coronary artery vasoconstriction 255
Adverse drug effects, 407
Afterload reduction, 79, 647
Aldosterone and adrenal renin, 463
Allopurinol and reperfusion arrhythmias, 295
Alpha-adrenergic blockade, 343, 355, 363, 369
Alpha-adrenergic receptors, 513
Amiodarone, 791
Amlodipine, 191
Amrinone, 401
Angina pectoris, 67, 343, 363
  Effort, *see* exercise-induced
  Exercise-induced, nitroglycerin ointment for, 831
  Exercise testing, 523
  Hypertension and, 369
  Medical treatment, 47
  Nitrate tolerance in, 823
  Resistance to therapy, 71
  Unstable, antiplatelet and anticoagulant therapy, 103
  Unstable, molsidomine for, 107
Angioplasty, 93
Angiotensin II, 453, 463
  Secretion of, 453
Anipamil, 191
Antianginal drugs, 47, 71, 831
  Combination, 47
  Coronary vasodilation in antianginal therapy, 27
  Nonresponsiveness, 71
  Resistance to, 71
  Silent pathophysiology, and, 47
Antiarrhythmic agents, 679, 791
  Prophylactic, 788
Anticoagulants, 103
Anti-oxidant enzymes and reperfusion arrhythmias, 295
Antiplatelet drugs, 35, 103
Arginine, 669
Arryhythmias, 295, 615,
  See reperfusion, 637, 801
  Prophylaxis after acute myocardial infarction, 788
Aspirin, 333
  Unstable angina, and, 103
Atenolol and ischemia in rat heart, 275, 501
Atherosclerosis, 281
  Fish oil, and, 281
ATP, 501
Atrial fibrillation
  Acetyl strophanthidin, and, 569
  Verapamil, and, 801
Atrial natriuretic factor, 487, 493
  mRNA for, 487
  Receptors for, 493
  Ventricular in salt-sensitive hypertension, 487
Atrial natriuretic peptide, 479
  See also atrial natriuretic factor
  Gene for, 479

Bepridil, 191
  Acute phase of myocardial infarction, and, 771
Beta-blockade, 139, 333
  After acute myocardial infarction, 355, 363, 369, 569
  Acute myocardial infarction, for, 113
  Infarct size in dog, and, 231
  Intrinsic sympathomimetic activity, 549
  Thrombolytic therapy for acute infarction, and, 601
Beta-adrenoceptor agonists, 245
Beta-adrenoceptor antagonists, *see* beta-blockade
Beta-adrenoceptors, 255, 513
Beta-receptor, 601
Blister suction technique, 561
Blood pressure, 269, 533
  Ambulatory monitoring, 533
  Twenty-four hour monitoring and verapamil, 533
Bradycardia-tachycardia syndrome, 165
Bronchospasm, 369

Calcium, 623, 637
  and blood pressure, 269
Calcium antagonists, 333, 539, 623, 771, 815
  Combination therapy, 177
  Contraindications, 177
  Drug interactions, 177
  Post-infarction, 139
  Second generation agents, 191
  Side-effects of, 177
  Thrombolytic therapy, and, 601
Calcium blockers, *see* calcium antagonists
Calcium channel antagonists, *see* calcium antagonists, 177, 191
Calcium entry blocking agents, *see* calcium antagonists, 601
Calcium ions and reperfusion arrhythmias, 623
Captopril for severe hypertension, 219, 287
Cardiac failure (also *see* congestive heart failure) 387, 647
Cardiac glycosides, 569
Cardiac myocytes, 479
Cardiac performance, 401

Cardiac transplant, 687
  Drug management, of, 687
Cardiotonic agents, 245
Catalase, 295
Celiprolol, hemodynamic comparison with enalapril, 211
Children with pulmonary hypertension, 661
Cholesterol, 795
Chronic heart failure, 407, 743
Cinnarazine, 191
Congenital heart disease, 661
Congestive heart failure, 221, 419, 493, 647, 727, 751
  Digitalization, 717
  Digoxin levels, 717
  Exercise, isometric for evaluation of vasodilators, 287
  Exercise testing, in, 653
  Ibopamine in, 221
  Influence of drug therapy, 419
  Inodilators for, 751
  Inotropic agents in, 83, 747
  OPC-8212 therapy for, 653
  Pathophysiologic profile, 397
  Patient self-assessment scores, in, 653,
  Quality of life, 419
  Risk profile, 387
  Vasodilatory therapy, in, 83, 287, 647
Converting enzyme inhibitor, 463
Coronary angioplasty, 93, 807
  Indications, 93
Coronary artery compared with saphenous vein, 325
  Vasoconstriction induced by ouabain, and, 255
Coronary artery disease, 61, 79, 355
Coronary artery bypass grafting, 93
  Aortacoronary bypass grafting, 561
Coronary artery ligation, 637
Coronary artery occlusion, 231, 313
Coronary circulation, 325
Coronary flow, 41
  Collateral flow, 313
Coronary occlusion and reperfusion ventricular arrhythmias, 513
Coronary steal phenomenon, 71
Coronary thrombolytic therapy, 121
Coronary vasodilation in antianginal therapy, 27
Creatine kinase, 127
CV-4151 on prostanoid formation and platelet aggregation, 693

Delayed afterdepolarizations, 623
Denervation sensitivity, 325
Deoxyglucose, 41
Digitalis, 413, 751
  Acetyl strophanthidin and atrial fibrillation, 569
  Conflicting data in trials, 727
  Congestive heart failure and, 743
  Toxicity in dog, 569
Digitalisation, 717
Digoxin, *see* also digitalis, 177, 717, 727, 733
  Digoxin-like substance in uremia, 757
  Interactions, 717
  Levels in congestive heart failure, 717
Dihydroquinidine and ventricular ectopy, 679
Dilitiazem and insulin release, 669
  Drug interactions, 177
  Ischemia in pigs, 815
  Side-effects and combinations, 177
Diphenylakylamines, 191
Diuretics, 219, 275, 413
Dobutamine, 401
Dopamine, 401
Drug benefits, 407
Dyspnea index, 419

Echocardiography, 211, 673
Effort angina, *see* exercise-induced angina
Electron spin resonance, 615
Enalapril, hemodynamic comparison with celiprolol, 211
Encainide and QT-prolongation, 283
Endothelial relaxing factor, 27
Endothelium, 35
  Endothelium-mediated coronary vasodilation, 27
Energy metabolism in ischemic rat heart, 501
Epidemiology, 387
Exercise, isometric for evaluation of vasodilators, 287
Exercise-induced angina, nitroglycerin ointment for, 831
Exercise testing for effects of oral nitroglycerin in angina pectoris, 523
Extracorporeal circulation and Starling forces, 561

Felodipine, 191
Fendiline, 191
Fish oil and atherosclerosis, 281
Flow-dependent dilation, 27
Forskolin, cardiac and vascular effects, 245
Free radicals, 295, 623
  Lipid peroxides and, 615
  Reperfusion and, 609

Gallopamil, 191
Glomerular arteriolar resistance
  Afferent, 539
  Efferent, 539
Glucose, 41, 669

Heart failure, *see* also congestive heart failure, 221, 529, 397, 401, 407, 733, 743
  Prognosis, of, 413
  Survival of, 413
  Therapeutic advances in, 413
Heart rate, 113
Hemodialysis and digoxin-like substance, 757
Hemodynamics, 401, 407, 539, 653
  Renal and intrarenal, 539
  Systemic, 539
Holter monitor ring, 679
Hypermagnesemia, electrophysiological effects, 637
Hypertension, 211, 269, 343, 463, 533
  Angina, 369
  Diuretics, 219
  Elderly, 275
  Experimental, 493
  Labetalol for, 369
  Pulmonary, 661
  Severe hypertension, captopril and verapamil for, 219
  Spontaneously hypertensive rats, and TA-3090, 539
Hypertrophy, 397

Ibopamine, 221
  Congestive heart failure, 221

Tolerance development, lack of, 221
Idiopathic dilated cardiomyopathy, 397
Infarct size, 231, 609, 815
Limitation, 313
Molsidomine, influence of, 127
Salvage index, 313
Inodilators compared with digitalis in heart failure, 751
Inotropes, 747
Inotropic agents, 83, 419
Inotropic substances in congestive heart failure, 83
Insulin release, 669
Intrinsic sympathomimetic activity and left ventricular function, 549
Ischemia, myocardial, 9, 17, 47, 103, 295, 313, 343, 355, 363, 513, 615, 771
Beta-blockers and ischemia in rat heart, 501
Calcium antagonists for, 815
Energy metabolism in, 501
Myocardium, of, 807
Oxygen radicals in, 761
Platelet-vessel wall interaction, 35
Post-infarction, 61
Silent, 61, 67
Tolerance, 815
Ischemic cardiomyopathy, 397
Ischemic heart disease
Preload or afterload reduction, 79
ISIS-1 trial and acute beta-blockade, 113
Isometric exercise for evaluation of vasodilatory therapy, 287
Isosorbide dinitrate, 529
Hemodynamic effects in pulmonary edema, 529
Spray vs tablets, 529
Isradipine, 191

Jelliffee equation, 717

Ketanserin and action potential duration, 239

Lebatolol, 363
Combined alpha and beta-blocking agent in ischemia, 343
Hemodynamics in ischemic heart disease, 355
Vasodilation and, 369
Left ventricular failure, *see* pulmonary edema
Left ventricular function and beta-blockade, 549
Lidocaine, 788
Lidoflazine, 191
Lipid peroxidation and reperfusion, 609, 615
Low density lipoproteins, 27

Magnesium and reperfusion arrhythmias, 637
MDL-19205 and mitral regurgitation, 305
Methyldopa, 275
Metroprolol, 205
Interaction with nitrendipine, verapamil, 205
Metabolism, 205
MIAMI trial and beta-blockade in acute infarction, 113
Mitral regurgitation and MDL-19205, 305
Molsidomine, 79
Enzyme evaluation, 127
Infarct size, 127
Mortality, 127
Unstable angina, 107
Myocardial infarction, 17, 93, 121
See also acute myocardial infarction, 761
Anterior, intravenous amiodarone and, 791
Bepidril and acute phase, 771
Beta-blockade, 113
Cholesterol control after, 795
Heart rate, 113
Secondary prevention after, 139
Myocardial ischemia, *see* ischemia
Myocardial metabolism, 9
Abnormalities in unstable angina, 41
Myocardial necrosis, 17, 313
Time course of, 17
Ultrastructure, 17
Verapamil and, 313
Myocardial oxygen demand, 113

Nadolol, 231
Necrosis, time course of myocardial, 17
Negative inotropic effect, 177
Nephrectomy, 463
Neurohumoral reflexes, 407
Neutrophils, 761
Nicardipine, 191
Insulin release, and, 669
Nifedipine, 79
Drug interactions, 177
Ischemia in pigs, and, 815
Pulmonary hypertension, for, 661
Side-effects and combinations, 177
Nimodipine, 191
Nisoldipine, 191
Intracoronary - effects on acute myocardial ischemia during angioplasty, 807
Intravenous - effects on LV function post-infarct, 673
Nitrates, 107, 333
Isosorbide dinitrate spray vs sublingual tablets, 529
Long-acting, 523
Tolerance in angina pectoris, 823
Nitrendipine, 191
Interaction with metoprolol, 205
Nitric oxide, 27
Nitroglycerin for angina pectoris, exercise testing of, 523
Nitroglycerin ointment and effort angina, 831
Nitrovasodilator action, 27
NMR study in myocardial ischemia in rat heart, 501
Norepinephrine, 255
Nuclear magentic resonance, 501
NYHA scale, 419

Obesity, calcium antagonists and insulin release, 669
OPC-8212 for congestive heart failure, 653
Ouabain and vasoconstriction in coronary artery, 255
Oxygen for pulmonary hypertension, 661
Oxygen cost diagram, 419
Oxygen imbalance, 9
Oxygen radicals in ischemia and reperfusion, 609, 761
See also free radicals

Parathyroid hormone, 269
Partial agonist activity, *see* intrinsic sympathomimetic activity
Percutaneous transluminal coronary angioplasty (PTCA),121, 807
Phenytoin, 171
Phosphodiesterase inhibitors, 413

Pindolol, 549
Plasminogen activators, 121
Platelets, 269
  Aggregation and CV-4151, 693
  Myocardial ischemia, and, 35
  Receptors, 493
  Vessel wall, 35
Positron emission tomography, 41
  Assessment of unstable angina, 41
Post-infarction
  Cholesterol control, 795
  Ischemia, 61
  Mortality, 139
  Prevention, 133, 139
Potassium loading, 463
Preload reduction, 79, 647
Pressure rate product, 831
Propranolol, 501, 549
  d-propranolol in ischemic rat heart, 501
  dl-propranolol in ischemic rat heart, 501
Prorenin, 463, 473
Prostaglandins, 693
Prostanoids and CV-4151 on inhibition of thromboxane synthetase, 693
Pulmonary congestion and nitrates, 529
Pulmonary edema and nitrates, 529
Pulmonary hypertension in children, nifedipine and oxygen for, 661

Quality of life in congestive heart failure, 419
Quinidine and ventricular ectopy, 679
QT-interval, 239
  Prolongation, 283

Radionuclide angiography, 673
Rand questions, 419
Receptor regulation and atrial natriuretic peptide, 493
Renin, 453
  Adrenal and aldosterone, 463
  Biosynthesis, 459
  Gene expression, 459
  Molecular biology, 459
  mRNA, 463
  Reproductive system, in, 473
  Synthesis in man, 459
Renin-angiotensin system, 453
  Intracellular function, 453
Reperfusion, 9, 17, 501
  Arrhythmias
    Adrenergic contributions, and, 513
    Allopurinol, and, 295
    Anti-oxidant enzymes, and, 295
    Calcium ions, and, 623
    Duration of coronary occulsion, and 513
  Calcium and, 623
  Damage, 609
  Free radicals and, 615
  Injury, 601, 761
  Magnesium, 637
  Oxygen radicals and, 761
  Ventricular arrhythmias, 513
Risk factors, 387

Salt hypertension and atrial natriuretic factor, 487
Saphenous vein graft compared with coronary artery, 325
SAS scale, 419
Second generation calcium antagonists, 191
Secondary prevention after myocardial infarction, 139
Serotonin antagonist, 239
Silent ischemia, 61, 67
  Methods for detection, 61
  Pain perception, 61
  Prognosis, 61
Sinoatrial node, 165
Sinus node dysfunction, 165
  Drug effects on sinus node, 165
Sodium depletion, 463
Spontaneously hypertensive rats (SHR), effects of TA-3090, 539
Superoxide dismutase, 295
Starling forces and extracorporeal circulation, 561
Streptokinase, 113
Sudden death, 387, 413
Sulfhydryl, 823
Systemic vascular resistance, 355

T-1583, compared with forskolin, 245
Ta-3090, hemodynamic effects in hypertensive rats, 539
Therapeutic implications, 397
Thrombolysis, 333, 601
Thrombolytic therapy, role of beta-blockers and calcium antagonists, 601
Thrombolytic therapy for acute myocardial infarction, 121
Thromboxane synthetase inhibitor, CV-4151, 693
Tiapamil, 191
Transcapillary forces, 561
Transient inward current, 623
Transplant, cardiac, drug management of, 687

Unstable angina, 93, 333
  Abnormalities in myocardial metabolism, 41
  Anticoagulant therapy, 103
  Aspirin therapy, 103
  Molsidomine for refractory unstable angina, 107
  Uremia, digoxin-like substance in serum, 757

Vagus nerve, 569
Vascular receptors, 493
Vascular smooth muscle, 325
Vasoconstriction, 255
Vasodilating substances, 83
Vasodilation, 373
  and labetalol, 369
Vasodilators, 83, 127, 419, 647
Vasopressin, 647
Ventricular arrhythmias, 171
Ventricular ectopy, 679
Ventricular fibrillation, 788
Ventricular tachycardia, 171
Verapamil, 219
  Drug interactions, 177
  Interaction with metoprolol, 205
  Ischemia in pigs, 815
  Metabolism, 205
  Myocardial necrosis, 313
  Side-effects and combinations, 177
  Sustained-release, 533
  Wolff-Parkinson-White syndrome and, 801

Wick technique, 561
Wolf-Parkinson-White syndrome and verapamil, 801

Xanthine oxidase, 761